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was performed on a FACSCANTO II cytometer (BD Biosciences, Le Pont de Claix, France) using DIVA 6.3 software for acquisition and analysis (BD Biosciences). For cell cycle assay, cells were fixed with 70% ethanol and incubated overnight at +4°C. Then, the cells were stained with 300 µl Phosphate buffer saline (PBS) (Gibco, Life Technologies, Saint-Aubin, France), 5 µl propidium iodide (Sigma Aldrich, Saint Quentin Fallavier, France) and 1 µl RNase (Sigma Aldrich) before cytometry acquisition (FC500, Beckman Coulter).
NF-κB pathway activation
CAL-1 cells (10 6 cells/ml) were incubated with bortezomib from 25 to 75 nM for 6 hours.
After fixation and permeabilization, NF-κB pathway stimulation was investigated through phosphorylated-NF-κB subunit RelA (pRelA) staining, using Alexa fluor 647 conjugated anti-NF-κB p65 (K10-895.12.50, BD Biosciences) antibody or isotype control (IgG2b kappa, MOPC 173, BD Biosciences) for experiments performed in vitro. An APC anti-NF-κB p65 (REA 348, Miltenyi Biotec, Bergisch Gladbach, Germany) antibody or its isotype control (REA control isotype APC) were used in PDX cells extracted from mouse blood after in vivo treatment 3 . In CAL-1 cells, nuclear and cytoplasmic pRelA expression was also evaluated by confocal microscopy using FV1000 confocal microscope (Olympus, Rungis, France) and analyzed with Olympus FV-viewer software, as described 3 . Cells were washed and immobilized into glass microscope slides by cytospin's centrifugation (1400 rpm, 5 min), before fixation and permeabilization using methanol (20 minutes at -20°C). Then, cells were washed 3 times with PBS 0,5% FBS solution, before staining with the primary antibody (anti-NF-κB p65 pS536, clone J144-460, BD Bioscience) followed by overnight incubation at 4°C with the secondary antibody (Alexa fluor 555-conjugated goat anti-mouse IgG (H+L), Life technologies, Gaithersburg, Maryland), for 1 hour at room temperature. Cell nuclei were stained with DAPI (Sigma Aldrich), and finally, cells were washed and mounted (Fluorescent Mounting Medium, Dako, Trappes, France) before acquisition.
Primary BPDCN cell xenograft model
Mice were then randomized and allocated to the two treatment groups namely: bortezomib 
Luciferase CAL-1 cell assay and in vivo bioluminescence imaging
The CAL-1 cell-line was transduced with a Luc-retroviral vector carrying Luciferase (Luc + ) and neomycin resistance (NeoR) genes. NOD/Shi-SCID/IL-2Rγc null (NOG mice, 6-8 weeks of age, CIEA, Japan) were injected intravenously with 0.5; 1 or 5.10 6 of Luc + CAL-1 cells (n=3/group). Transduced cells were then cloned at 0.3 cells/well. Two luciferaseexpressing (Luc + ) cell clones were harvested according to their luminescence intensity emission measured using the NightOwl LB983 imaging system and analyzed with the WinLightTM software 5 (Berthold technologies, Germany). NOD/Shi-SCID/IL-2Rγcnull (NOG mice, 6-8 weeks of age, CIEA, Japan, total n=9 mice)
were injected intravenously with 0.5; 1 or 5.106 of Luc + CAL-1, (n=3/group). E-luciferin (Promega, Lyon, France) was injected into the mouse peritoneal cavity (150 mg/kg) 10 minutes prior imaging. Circulating Luc + CAL-1 cells were monitored by flow cytometry.
Monitoring of Luc + CAL-1 cell tumor burden was performed at day 6, 8, 12, and 15 by measuring luciferase activity after luciferin infusion by total body bioluminescence imaging (BLI, NightOwl). BLI and WinLight analysis (photon flux) allowed us to evaluate CAL-1 cell tumor burden at day 6, 8, 12, and 15. At the end of the experiment, mice were euthanized and different organs (the lungs, bone marrow, the spleen, the liver, kidneys, the pancreas, spinal cord, ovary, and lymph nodes) were harvested and imaged by BLI. Leukemic cell morphology was performed on cytospins from murine blood or spleen samples after May Grunwald Giemsa staining (Sigma-Aldrich), as described 4 .
Statistical analysis
Data were presented as the mean + Standard Error of the Mean (SEM). A p value <0.05 was considered statistically significant. 
